Triantafyllias Konstantinos, Thiele Leif-Erik, Cavagna Lorenzo, Baraliakos Xenofon, Bertsias George, Schwarting Andreas
Rheumatology Center Rhineland-Palatinate, Kaiser-Wilhelm-Str. 9-11, 55543 Bad Kreuznach, Germany.
Department of Internal Medicine I, Division of Rheumatology and Clinical Immunology, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany.
Diagnostics (Basel). 2023 May 26;13(11):1870. doi: 10.3390/diagnostics13111870.
The increased cardiovascular (CV) risk among patients with autoimmune rheumatic diseases, such as arthritides and connective tissue diseases, has been extensively documented. From a pathophysiological standpoint, systemic inflammation in the context of the disease can lead to endothelial dysfunction, accelerated atherosclerosis, and structural changes in vessel walls, which, in turn, are associated with exaggerated CV morbidity and mortality. In addition to these abnormalities, the increased prevalence of traditional CV risk factors, such as obesity, dyslipidemia, arterial hypertension, and impaired glucose metabolism, can further worsen the status of and overall prognosis for CV in rheumatic patients. However, data on appropriate CV screening methods for patients with systemic autoimmune diseases are scarce, and traditional algorithms may lead to an underestimation of the true CV risk. The reason for this is that these calculations were developed for the general population and thus do not take into account the effect of the inflammatory burden, as well as other chronic-disease-associated CV risk factors. In recent years, different research groups, including ours, have examined the value of different CV surrogate markers, including carotid sonography, carotid-femoral pulse wave velocity, and flow-mediated arterial dilation, in the assessment of CV risk in healthy and rheumatic populations. In particular, arterial stiffness has been thoroughly examined in a number of studies, showing high diagnostic and predictive value for the occurrence of CV events. To this end, the present narrative review showcases a series of studies examining aortic and peripheral arterial stiffness as surrogates of all-cause CV disease and atherosclerosis in patients with rheumatoid and psoriatic arthritis, as well as in systemic lupus erythematosus and systemic sclerosis. Moreover, we discuss the associations of arterial stiffness with clinical, laboratory, and disease-specific parameters.
自身免疫性风湿疾病(如关节炎和结缔组织病)患者心血管(CV)风险增加,这已得到广泛记录。从病理生理学角度来看,疾病背景下的全身炎症可导致内皮功能障碍、动脉粥样硬化加速以及血管壁结构改变,进而与CV发病率和死亡率升高相关。除了这些异常情况外,肥胖、血脂异常、动脉高血压和糖代谢受损等传统CV危险因素患病率增加,可进一步恶化风湿患者的CV状况和总体预后。然而,关于系统性自身免疫疾病患者合适的CV筛查方法的数据很少,传统算法可能会低估真实的CV风险。原因在于这些计算是针对一般人群开发的,因此没有考虑炎症负担以及其他与慢性疾病相关的CV危险因素的影响。近年来,包括我们在内的不同研究团队研究了不同CV替代标志物(包括颈动脉超声、颈股脉搏波速度和血流介导的血管舒张)在评估健康人群和风湿人群CV风险中的价值。特别是,动脉僵硬度已在多项研究中得到深入研究,显示出对CV事件发生具有较高的诊断和预测价值。为此,本叙述性综述展示了一系列研究,这些研究将主动脉和外周动脉僵硬度作为类风湿性关节炎、银屑病关节炎、系统性红斑狼疮和系统性硬化症患者全因CV疾病和动脉粥样硬化的替代指标。此外,我们还讨论了动脉僵硬度与临床、实验室及疾病特异性参数之间的关联。